HC Wainwright Reiterates Buy Rating for Iterum Therapeutics (NASDAQ:ITRM)

HC Wainwright reiterated their buy rating on shares of Iterum Therapeutics (NASDAQ:ITRM) in a research report sent to investors on Tuesday morning, Benzinga reports. They currently have a $6.00 target price on the stock.

Iterum Therapeutics Price Performance

Shares of Iterum Therapeutics stock traded down $0.03 on Tuesday, hitting $1.55. The company’s stock had a trading volume of 46,917 shares, compared to its average volume of 481,742. The company has a market capitalization of $25.67 million, a price-to-earnings ratio of -0.52 and a beta of 2.33. Iterum Therapeutics has a 1 year low of $0.62 and a 1 year high of $2.50. The firm has a fifty day moving average price of $1.53 and a 200-day moving average price of $1.52. The company has a debt-to-equity ratio of 3.63, a quick ratio of 1.89 and a current ratio of 1.89.

Iterum Therapeutics (NASDAQ:ITRM) last announced its earnings results on Thursday, March 28th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.08. As a group, sell-side analysts anticipate that Iterum Therapeutics will post -1.75 earnings per share for the current fiscal year.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.